In the mid-1990s, Amgen scientists pioneered research that
changed the understanding of bone biology.
Amgen researchers W. Scott Simonet, David Lacey, and William J. Boyle published the first description of osteoprotegerin in a 1997 Cell paper1. Further research led to the identification of the RANK Ligand pathway.
That discovery has been fundamental not only to Amgen's commitment to furthering our understanding of the science of bone biology, but also to the work of many of researchers around the world.